Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth M Williams

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Rheumatology|November 17, 2015
Barriers to Care in Gout: From Prescriber to PatientStefanie Vaccher, Diluk R W Kannangara, Melissa T Baysari, et al.
British Journal of Clinical Pharmacology|November 22, 2011
Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney diseaseDiluk R W Kannangara, Darren M Roberts, Timothy J Furlong, et al.
British Journal of Clinical Pharmacology|February 4, 2012
The pharmacokinetics of oxypurinol in people with goutSophie L Stocker, Andrew J McLachlan, Radojka M Savic, et al.
Drug Safety|April 4, 2013
The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of PathogenesisJanna K Duong, Timothy J Furlong, Darren M Roberts, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2020
Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposureRashmi V Shingde, Stephanie E Reuter, Garry G Graham, et al.
Therapeutic Drug Monitoring|November 23, 2013
An audit of a therapeutic drug monitoring service for allopurinol therapyDiluk R W Kannangara, Sheena N Ramasamy, John E Ray, et al.
British Journal of Clinical Pharmacology|July 18, 2022
Population pharmacokinetic modelling of febuxostat in healthy subjects and people with goutBishoy Kamel, Ahmad Y Abuhelwa, David Foster, et al.
British Journal of Clinical Pharmacology|May 10, 2020
A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjectsBishoy Kamel, Garry G Graham, Sophie L Stocker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
Antiviral Therapy|March 27, 2009
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patientsSarah L Pett, Michael C McCarthy, David A Cooper, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Rheumatology|November 17, 2015
Barriers to Care in Gout: From Prescriber to PatientStefanie Vaccher, Diluk R W Kannangara, Melissa T Baysari, et al.
British Journal of Clinical Pharmacology|November 22, 2011
Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney diseaseDiluk R W Kannangara, Darren M Roberts, Timothy J Furlong, et al.
British Journal of Clinical Pharmacology|February 4, 2012
The pharmacokinetics of oxypurinol in people with goutSophie L Stocker, Andrew J McLachlan, Radojka M Savic, et al.
Drug Safety|April 4, 2013
The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of PathogenesisJanna K Duong, Timothy J Furlong, Darren M Roberts, et al.
The Journal of Antimicrobial Chemotherapy|August 14, 2020
Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposureRashmi V Shingde, Stephanie E Reuter, Garry G Graham, et al.
Therapeutic Drug Monitoring|November 23, 2013
An audit of a therapeutic drug monitoring service for allopurinol therapyDiluk R W Kannangara, Sheena N Ramasamy, John E Ray, et al.
British Journal of Clinical Pharmacology|July 18, 2022
Population pharmacokinetic modelling of febuxostat in healthy subjects and people with goutBishoy Kamel, Ahmad Y Abuhelwa, David Foster, et al.
British Journal of Clinical Pharmacology|May 10, 2020
A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjectsBishoy Kamel, Garry G Graham, Sophie L Stocker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
Antiviral Therapy|March 27, 2009
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patientsSarah L Pett, Michael C McCarthy, David A Cooper, et al.
Pageof 7